Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial
Daniel M.F. Claassens, Pim W. M. van Dorst, Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, Richard M. Tjon Joe Gin, Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Maarten J. Postma, Vera H.M. Deneer, Jurriën M. ten Berg, Cornelis Boersma
Topics & Concepts
TicagrelorMedicinePrasugrelQuality-adjusted life yearCost effectivenessConventional PCICohortCost-effectiveness analysisPercutaneous coronary interventionP2Y12Myocardial infarctionInternal medicineRisk analysis (engineering)Antiplatelet Therapy and Cardiovascular DiseasesPharmacogenetics and Drug MetabolismBlood Coagulation and Thrombosis Mechanisms